Asset Details
Do you wish to reserve the book?
Identification of Hydroxysteroid (17 beta ) dehydrogenase type 12 (HSD17B12) as a CD8 super(+) T-cell-defined human tumor antigen of human carcinomas
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of Hydroxysteroid (17 beta ) dehydrogenase type 12 (HSD17B12) as a CD8 super(+) T-cell-defined human tumor antigen of human carcinomas
Do you wish to request the book?
Identification of Hydroxysteroid (17 beta ) dehydrogenase type 12 (HSD17B12) as a CD8 super(+) T-cell-defined human tumor antigen of human carcinomas
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of Hydroxysteroid (17 beta ) dehydrogenase type 12 (HSD17B12) as a CD8 super(+) T-cell-defined human tumor antigen of human carcinomas
2011
Overview
Hydroxysteroid (17 beta ) dehydrogenase type 12 (HSD17B12) is a multifunctional isoenzyme functional in the conversion of estrone to estradiol (E2), and elongation of long-chain fatty acids, in particular the conversion of palmitic to archadonic (AA) acid, the precursor of sterols and the inflammatory mediator, prostaglandin E sub(2). Its overexpression together with that of COX-2 in breast carcinoma is associated with a poor prognosis. We have identified the HSD17B12 sub(114-122) peptide (IYDKIKTGL) as a naturally presented HLA-A*0201 (HLA-A2)-restricted CD8 super(+) T-cell-defined epitope. The HSD17B12 sub(114-122) peptide, however, is poorly immunogenic in its in vitro ability to induce peptide-specific CD8 super(+) T cells. Acting as an \"optimized peptide\", a peptide (TYDKIKTGL), which is identical to the HSD17B12 sub(114-122) peptide except for threonine at residue 1, was required for inducing in vitro the expansion of CD8 super(+) T-cell effectors cross-reactive against the HSD17B12 sub(114-122) peptide. In IFN- gamma ELISPOT assays, these effector cells recognize HSD17B12 sub(114-122) peptide-pulsed target cells, as well as HLA-A2 super(+) squamous cell carcinoma of the head and neck (SCCHN) and breast carcinoma cell lines overexpressing HSD17B12 and naturally presenting the epitope. Whereas growth inhibition of a breast carcinoma cell line induced by HSD17B12 knockdown was only reversed by AA, in a similar manner, the growth inhibition of the SCCHN PCI-13 cell line by HSD17B12 knockdown was reversed by E2 and AA. Our findings provide the basis for future studies aimed at developing cancer vaccines for targeting HSD17B12, which apparently can be functional in critical metabolic pathways involved in inflammation and cancer.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.